BioXcel Therapeutics Inc.:Bxcl501在治疗阿片类药物戒断症状中展现出临床获益与良好耐受性

美股速递
Mar 05

BioXcel Therapeutics Inc.公布的最新临床数据显示,其研究性药物Bxcl501在治疗阿片类药物戒断症状方面表现出显著的临床益处和良好的耐受性特征。该结果突显了该疗法在应对这一严峻公共卫生挑战方面的潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10